Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global RNA Targeting Small Molecules Therapeutics Market Valued at Present and by 2029?

There has been a consistent expansion in the market size for influenza treatment over the recent past. The market is projected to increase from $6.6 billion in 2024 to $6.83 billion in 2025, registering a compound annual growth rate (CAGR) of 3.4%. Factors contributing to the growth during the historic period include the rise in yearly influenza instances, enhanced government support for influenza study and readiness initiatives, campaigns to raise public awareness about vaccination, the establishment of worldwide influenza monitoring systems, and an expansion in healthcare facilities.

In the forthcoming years, a stable growth in the influenza treatment market is anticipated, escalating to “ $7.93 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 3.8%. Factors contributing to this advancement within the forecast period include the launch of novel antiviral medications and treatment methods, the broadening of vaccination schemes, ongoing enlargement and enhancement of healthcare infrastructure, the rising population of the elderly, and the creation of innovative treatments. Key trends during the forecast period encompass strides towards the development of universal vaccines, breakthroughs in vaccine delivery technologies, the incorporation of AI and big data, progress in personalized healthcare, and heightened alliances among pharmaceutical firms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp

#What Drivers Are Influencing Growth In The RNA Targeting Small Molecules Therapeutics Market?

The rise in cancer instances is predicted to accelerate the growth of the RNA-targeting small molecule therapeutics market. Cancer encompasses a variety of diseases that can arise in almost any organ or tissue when abnormal cells multiply uncontrollably, surpassing their usual constraints and either infiltrating other organs or intruding into adjacent body components. RNA-targeting small molecules, which are designed and studied to selectively target RNA sequences associated with cancer, are used in cancer treatment. For example, research issued by the American Cancer Society, a health organization based in the US, stated in January 2022 that approximately 609,360 cancer-related deaths and 1.9 million new cancer cases are predicted in the US in 2022, averaging about 1,670 deaths daily. As a result, the RNA-targeting small molecule therapeutics market’s growth is being fueled by the escalating number of cancer cases.

The influenza treatment market covered in this report is segmented –

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products

2) By Route Of Administration: Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Peramivir: Intravenous Peramivir, Peramivir Injection

2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler

3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension

4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension

5) Other Products: Rimantadine, Amantadine

What Future Market Trends Are Projected For The RNA Targeting Small Molecules Therapeutics Industry?

Major corporations in the influenza treatment market are striving to extend their product offerings by introducing inventive products such as single-dose oral medication for flu treatment. This strategy aims to increase patient adherence, improve efficacy of the treatment, and gain a sizable portion of the market. Single-dose oral medication is a drug developed to manage influenza with just a single oral intake, thereby streamlining the treatment process. For example, in August 2022, the biotechnology firm Genentech Inc., which is based in the U.S., declared the approval of Xofluza (Baloxavir Marboxil) by the U.S. Food and Drug Administration (FDA). Xofluza happens to be the first one-dose oral medication that provides a practical and efficient approach to controlling acute uncomplicated influenza in children aged five to slightly under 12 years who have shown symptoms for no longer than 48 hours, along with other respiratory viruses.

Which Companies Play A Key Role In The Development Of The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

What Are The Key Regional Developments Shaping The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the influenza treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15832&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model